Skip to main content
Erschienen in: Reactions Weekly 1/2017

01.09.2017 | Case report

Vedolizumab

Increased rectal bleeding: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Amiot A, et al. Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 14: 1593-1601, No. 11, Nov 2016. Available from: URL: http://doi.org/10.1016/j.cgh.2016.02.016 - France Amiot A, et al. Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 14: 1593-1601, No. 11, Nov 2016. Available from: URL: http://​doi.​org/​10.​1016/​j.​cgh.​2016.​02.​016 - France
Metadaten
Titel
Vedolizumab
Increased rectal bleeding: case report
Publikationsdatum
01.09.2017
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2017
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-017-35884-z

Weitere Artikel der Ausgabe 1/2017

Reactions Weekly 1/2017 Zur Ausgabe

Case report

Paclitaxel

Case report

Psma-617

Case report

Daratumumab

Case report

Vedolizumab